Sublingual Semaglutide (generic OzempicĀ®) now available! Get Started
Dashboard
Formulas

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation is designed to gradually release the medication over an extended period, providing sustained therapeutic effects and improved patient compliance. These capsules are used to treat conditions such as Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy.

Want a different strength?
Click the Text Us button below.
To prescribe, you must be a verified prescriber.
To prescribe, you must be in a state where we hold an active out-of-state pharmacy license.
Starting at
Must be E-Prescribed
Get Started
Generate LeafletShow Leaflet
This medication requires a prescription from your doctor
Are you a prescriber? Sign Up
Trusted by 60,357 patients to date.
A group of faces of our past satisfied patients.
A svg symbol of a mortar and pestle with ingredients going in.
Custom made in our compounding labs.
Sliders that show the customization of ingredients.
Personalized treatment for better results.
User with a gear showing the personalization of the formulation.
All strengths and ingredients are tailored to your needs.
This medication is not available at retail pharmacies. It is compounded, and may be more effective at treating you or your patient.
Slow Release Capsules
6427079ea643243e1b518813
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Loading icon rotating.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Dosing Calculator

Get general dosing information for a patient by using this calculator.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Loading icon rotating.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Formula Information

A small arrow pointing down

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded medication specifically designed to treat a range of neurological conditions, including Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. This unique formulation utilizes Methocel E4M, a controlled-release polymer, to ensure a gradual and sustained release of the active ingredients, Carbidopa and Levodopa, over an extended period of time.

The slow release mechanism of this formulation offers several benefits. It provides a steady therapeutic effect, reduces the frequency of dosing, and improves patient compliance, particularly for those requiring a controlled and prolonged release profile. The combination of Carbidopa and Levodopa in this formulation is designed to minimize the metabolism of Levodopa in the body, thereby enhancing the efficient delivery of the medication to the brain.

As a result, this formulation can effectively alleviate symptoms associated with these neurological conditions, such as tremors, stiffness, and difficulty with movement. It is a testament to the advancements in pharmaceutical compounding and its potential in providing personalized treatment options for patients.

At Bayview Pharmacy, we are committed to offering this innovative formulation to our patients. Our team of compounding pharmacists are well-versed in the intricacies of this medication and are available to answer any questions you may have about Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules and its role in managing your condition. Please do not hesitate to reach out to us for any queries or concerns.

Drug Interactions

A small arrow pointing down

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded formulation specifically designed for the treatment of neurological disorders such as Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. The capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the encapsulated medication over an extended period of time. This slow and steady release offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.

Carbidopa is an inhibitor of aromatic amino acid decarboxylase, an enzyme responsible for the conversion of levodopa to dopamine. Dopamine is a neurotransmitter that is deficient in patients with Parkinson's Disease. By inhibiting this enzyme, Carbidopa reduces the peripheral metabolism of levodopa, allowing more of the drug to reach the brain and exert its therapeutic effects. This formulation is designed to provide a slow and steady release of levodopa, which helps to reduce the occurrence of side effects such as nausea and vomiting.

It is important to note that this formulation should not be used in combination with other dopaminergic medications, as this may increase the risk of adverse effects. Patients should also be monitored for signs of neuroleptic malignant syndrome, a rare but potentially fatal side effect of levodopa. If you have any questions about the use of Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules for the treatment of Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, or Progressive Supranuclear Palsy, please consult with a healthcare professional.

How Does it Work

A small arrow pointing down

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded formulation of two medications, Carbidopa and Levodopa, used in the treatment of various neurological conditions. These conditions include Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. The combination of these two medications works synergistically to manage the symptoms of these conditions.

Carbidopa is an inhibitor of the enzyme aromatic amino acid decarboxylase, which is responsible for the conversion of levodopa to dopamine. By inhibiting this enzyme, Carbidopa ensures that more Levodopa is available to be converted into dopamine in the brain. Levodopa, on the other hand, is a precursor of dopamine, a neurotransmitter that is deficient in patients with Parkinson's Disease and other similar conditions.

The unique feature of this formulation is its slow-release mechanism. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This polymer is designed to release the encapsulated medication or active ingredient gradually over an extended period of time. This slow-release formulation provides a steady release of the medication, allowing for more consistent symptom control. It offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.

When taken as directed, Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules can help to reduce the symptoms of the aforementioned neurological conditions. The medication works by increasing the amount of dopamine available in the brain, which helps to improve motor control and reduce tremors, stiffness, and other symptoms associated with these conditions.

It is important to note that Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules should not be used to treat any other condition. The dosage and frequency of administration will vary depending on the individual and the condition being treated. It is crucial to take the medication as prescribed and not to change the dosage or frequency without consulting your healthcare provider.

If you have any questions about Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules or how it works to treat Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, or Progressive Supranuclear Palsy, please consult with your healthcare provider or pharmacist.

Other Uses

A small arrow pointing down

Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded formulation designed to provide a controlled and prolonged release of the active ingredients. This is achieved through the use of Methocel E4M, a type of controlled-release polymer. The slow release of the medication offers sustained therapeutic effects, which can lead to reduced dosing frequency and improved patient compliance, particularly beneficial for medications requiring a controlled release profile.

This formulation is primarily used in the management of Parkinson's disease, but it may also be beneficial in treating other neurological conditions such as tardive dyskinesia, Huntington's disease, and Tourette's syndrome. Additionally, it may be used to alleviate symptoms of depression, anxiety, and insomnia.

It is important to note that this formulation is not recommended for use in children under the age of 18. Patients taking this medication should be closely monitored for any adverse reactions, which may include nausea, vomiting, dizziness, and confusion. Furthermore, any changes in mental health, such as suicidal thoughts or behavior, should be promptly reported to a healthcare provider.

Patients are advised to take the medication as prescribed and to not discontinue its use without consulting their healthcare provider. If you have any questions or concerns about the use of Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules, it is recommended to reach out to a healthcare professional for further guidance.

Frequently Asked Questions

A small arrow pointing down

What is the Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsule?

This is a compounded formulation of two medications, Carbidopa and Levodopa, encapsulated in a controlled-release polymer called Methocel E4M. This formulation is designed to gradually release the medication over an extended period of time.

What is the purpose of the Methocel E4M in this formulation?

Methocel E4M is a type of controlled-release polymer. It is used in this formulation to ensure that the medication is released gradually over a prolonged period, offering sustained therapeutic effects and reducing the frequency of dosing.

What are the benefits of a slow-release formulation?

Slow-release formulations offer several benefits. They provide sustained therapeutic effects, reduce the frequency of dosing, and improve patient compliance, especially for medications that require a controlled and prolonged release profile.

How often do I need to take this medication?

As this is a slow-release formulation, the frequency of dosing is typically reduced. However, the exact dosing schedule should be determined by your healthcare provider based on your specific medical condition and response to therapy.

What is the role of Carbidopa in this formulation?

Carbidopa is used in combination with Levodopa to treat the symptoms of Parkinson's disease. It works by preventing the breakdown of Levodopa in the body, allowing more Levodopa to reach the brain and reduce the symptoms of Parkinson's disease.

What is the role of Levodopa in this formulation?

Levodopa is a medication used to treat the symptoms of Parkinson's disease. It works by being converted to dopamine in the brain, helping to control movement and reduce symptoms such as shakiness, stiffness, and difficulty with walking.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose to catch up. Always consult your healthcare provider to ensure the information applies to your personal circumstances.

What are the potential side effects of this medication?

Side effects may include nausea, vomiting, loss of appetite, and feeling lightheaded. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Can I take this medication with other drugs?

Before starting this medication, tell your doctor or pharmacist of all the drugs you are taking, especially of certain anti-seizure drugs, antipsychotic drugs, and high blood pressure medications. Drug interactions may change how your medications work or increase your risk for serious side effects.

Can I stop taking this medication abruptly?

Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Your dose may need to be gradually reduced.

Related Formulas

Related Products
Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

No compounded medications are reviewed by the FDA for safety or efficacy.